Stress‑induced catecholamines attenuate sorafenib efficacy by inhibiting ferroptosis in β2‑adrenergic receptor positive renal cell carcinoma.

IF 7.3 3区 医学 Q1 ONCOLOGY
International journal of oncology Pub Date : 2026-08-01 Epub Date: 2026-06-26 DOI:10.3892/ijo.2026.5905
Masaki Ushijima, Sei Naito, Hiromi Ito, Takafumi Narisawa, Osamu Ichiyanagi, Hidenori Kanno, Hiroki Fukuhara, Yuki Takai, Mayu Yagi, Atushi Yamagishi, Hayato Nishida, Yutaro Obara, Norihiko Tsuchiya
{"title":"Stress‑induced catecholamines attenuate sorafenib efficacy by inhibiting ferroptosis in β2‑adrenergic receptor positive renal cell carcinoma.","authors":"Masaki Ushijima, Sei Naito, Hiromi Ito, Takafumi Narisawa, Osamu Ichiyanagi, Hidenori Kanno, Hiroki Fukuhara, Yuki Takai, Mayu Yagi, Atushi Yamagishi, Hayato Nishida, Yutaro Obara, Norihiko Tsuchiya","doi":"10.3892/ijo.2026.5905","DOIUrl":null,"url":null,"abstract":"<p><p>Ferroptosis, an iron‑dependent form of non‑apoptotic cell death, is a potential target for cancer therapy. Sorafenib, a molecular targeted agent for renal cell carcinoma (RCC), is involved in ferroptosis induction. Chronic stress, mediated by catecholamines via β2‑adrenergic receptors (ADRB2), promotes cancer progression, yet its influence on drug resistance and ferroptosis remains elusive. To investigate ADRB expression in RCC, immunohistochemistry of surgical specimens was performed and assessed ADRB mRNA and protein levels were assessed by RT‑qPCR and western blotting in RCC cell lines. To determine whether β‑adrenergic signaling modulates sorafenib sensitivity, we used ADRB2‑expresing ACHN cells and conducted MTS cell viability assays following β‑adrenergic agonist isoproterenol (ISO) stimulation, ADRB2 knockdown by siRNA, as well as a restraint‑stress mouse model in which catecholamine levels were elevated, bearing ACHN cells or ACHN cells with ADRB2 knockdown by shRNA. To evaluate the involvement of ferroptosis, we applied the ferroptosis inhibitor ferrostatin‑1 (Fer‑1) and inducers erastin and RSL3, and measured cell viability, malondialdehyde and reactive oxygen species. To elucidate the mechanism underlying the ISO effect on ferroptosis, MAPK pathway activity was assessed by western blotting and MTS assays performed under MAPK inhibition. The present study confirmed ADRB2 expression in RCC by immunohistochemistry of surgical specimens. Using the ADRB2‑expressing RCC cell line ACHN, the present study demonstrated that stimulation with the β‑adrenergic agonist isoproterenol (ISO) conferred resistance to sorafenib both <i>in vitro</i> and in a mouse stress model; this effect was abrogated by ADRB2 knockdown. Similarly to ISO, Fer‑1 diminished sorafenib sensitivity in ACHN cells. Erastin and RSL3 markedly decreased cell viability, however, ISO attenuated ferroptosis in ACHN cells. Mechanistically, ISO inhibited the phosphorylation of ERK1/2, p38 and JNK, all of which contribute to ferroptosis suppression. These findings provide evidence that chronic stress‑induced ADRB2 activation promotes sorafenib resistance by mitigating ferroptotic cell death.</p>","PeriodicalId":14175,"journal":{"name":"International journal of oncology","volume":"69 2","pages":""},"PeriodicalIF":7.3000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13344368/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/ijo.2026.5905","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Ferroptosis, an iron‑dependent form of non‑apoptotic cell death, is a potential target for cancer therapy. Sorafenib, a molecular targeted agent for renal cell carcinoma (RCC), is involved in ferroptosis induction. Chronic stress, mediated by catecholamines via β2‑adrenergic receptors (ADRB2), promotes cancer progression, yet its influence on drug resistance and ferroptosis remains elusive. To investigate ADRB expression in RCC, immunohistochemistry of surgical specimens was performed and assessed ADRB mRNA and protein levels were assessed by RT‑qPCR and western blotting in RCC cell lines. To determine whether β‑adrenergic signaling modulates sorafenib sensitivity, we used ADRB2‑expresing ACHN cells and conducted MTS cell viability assays following β‑adrenergic agonist isoproterenol (ISO) stimulation, ADRB2 knockdown by siRNA, as well as a restraint‑stress mouse model in which catecholamine levels were elevated, bearing ACHN cells or ACHN cells with ADRB2 knockdown by shRNA. To evaluate the involvement of ferroptosis, we applied the ferroptosis inhibitor ferrostatin‑1 (Fer‑1) and inducers erastin and RSL3, and measured cell viability, malondialdehyde and reactive oxygen species. To elucidate the mechanism underlying the ISO effect on ferroptosis, MAPK pathway activity was assessed by western blotting and MTS assays performed under MAPK inhibition. The present study confirmed ADRB2 expression in RCC by immunohistochemistry of surgical specimens. Using the ADRB2‑expressing RCC cell line ACHN, the present study demonstrated that stimulation with the β‑adrenergic agonist isoproterenol (ISO) conferred resistance to sorafenib both in vitro and in a mouse stress model; this effect was abrogated by ADRB2 knockdown. Similarly to ISO, Fer‑1 diminished sorafenib sensitivity in ACHN cells. Erastin and RSL3 markedly decreased cell viability, however, ISO attenuated ferroptosis in ACHN cells. Mechanistically, ISO inhibited the phosphorylation of ERK1/2, p38 and JNK, all of which contribute to ferroptosis suppression. These findings provide evidence that chronic stress‑induced ADRB2 activation promotes sorafenib resistance by mitigating ferroptotic cell death.

应激诱导的儿茶酚胺通过抑制β2 -肾上腺素能受体阳性肾细胞癌中的铁下垂来减弱索拉非尼的疗效。
铁下垂是一种非凋亡细胞死亡的铁依赖性形式,是癌症治疗的潜在靶点。索拉非尼是一种用于肾细胞癌(RCC)的分子靶向药物,参与铁下垂诱导。慢性应激,由儿茶酚胺通过β2 -肾上腺素能受体(ADRB2)介导,促进癌症进展,但其对耐药和铁死亡的影响尚不清楚。为了研究ADRB在RCC中的表达,我们对手术标本进行免疫组化,并通过RT - qPCR和western blotting检测RCC细胞系中ADRB mRNA和蛋白的表达水平。为了确定β -肾上腺素能信号传导是否调节索拉非尼的敏感性,我们使用了表达ADRB2的ACHN细胞,并在β -肾上腺素能激动剂异丙肾上腺素(ISO)刺激、ADRB2被siRNA敲低、儿茶酚胺水平升高、ACHN细胞或ADRB2被shRNA敲低的ACHN细胞的抑制应激小鼠模型下进行了MTS细胞活力测定。为了评估铁下垂的参与程度,我们使用了铁下垂抑制剂ferstatin - 1 (Fer - 1)和诱变剂erastin和RSL3,并测量了细胞活力、丙二醛和活性氧。为了阐明ISO对铁下垂作用的机制,在MAPK抑制的情况下,通过western blotting和MTS检测来评估MAPK途径的活性。本研究通过手术标本的免疫组化证实了ADRB2在RCC中的表达。利用表达ADRB2的RCC细胞系ACHN,本研究证明β -肾上腺素能激动剂异丙肾上腺素(ISO)的刺激在体外和小鼠应激模型中都能产生对索拉非尼的抗性;这种作用被ADRB2敲除。与ISO类似,Fer‑1降低了ACHN细胞对索拉非尼的敏感性。Erastin和RSL3显著降低细胞活力,而ISO则减轻ACHN细胞的铁下垂。在机制上,ISO抑制ERK1/2、p38和JNK的磷酸化,这些磷酸化都有助于抑制铁下垂。这些发现提供了证据,证明慢性应激诱导的ADRB2激活通过减轻嗜铁细胞死亡来促进索拉非尼耐药。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.60
自引率
0.00%
发文量
157
审稿时长
2.1 months
期刊介绍: The main aim of Spandidos Publications is to facilitate scientific communication in a clear, concise and objective manner, while striving to provide prompt publication of original works of high quality. The journals largely concentrate on molecular and experimental medicine, oncology, clinical and experimental cancer treatment and biomedical research. All journals published by Spandidos Publications Ltd. maintain the highest standards of quality, and the members of their Editorial Boards are world-renowned scientists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书